On 1 February 2023, the minister of health announced the appointment of Thomas J Digby as the new chairperson for the Patented Medicine Prices Review Board for a five-year term. Digby is:

a lawyer with expertise in intellectual property and has an extensive educational background in the Biological Sciences. He has over 25 years of experience working with the pharmaceutical sector and is highly knowledgeable regarding patented medicines.

The formal role of chairperson had been vacant since Dr Mitchell Levine completed his five-year term in November 2021. The acting chairperson, Mélanie Bourassa Forcier, resigned in December 2022.

On 3 February 2023, the pan-Canadian Pharmaceutical Alliance (pCPA) announced that it is recruiting a chief executive officer (CEO) as part of its transition to a standalone organisation. The new CEO is expected to be in place in Spring 2023. Further to the pCPA's strategic plan released in April 2022, a standalone pCPA corporation has been created, and a board representing participating governments has been appointed.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.